Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification

Inge Van Der Werf, Anna Wojtuszkiewicz, Manja Meggendorfer, Stephan Hutter, Constance Baer, Martijn Heymans, Peter J.M. Valk, Wolfgang Kern, Claudia Haferlach, Jeroen J.W.M. Janssen, Gert J. Ossenkoppele, Jacqueline Cloos, Torsten Haferlach

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

25 Citaten (Scopus)


Splicing factor (SF) mutations are important contributors to the pathogenesis of hematological malignancies; however, their relevance in risk classification of acute myeloid leukemia (AML) warrants further investigation. To gain more insight into the characteristics of patients with AML carrying SF mutations, we studied their association with clinical features, cytogenetic and molecular abnormalities, and clinical outcome in a large cohort of 1447 patients with AML and high-risk myelodysplastic syndrome. SF mutations were identified in 22% of patients and were associated with multiple unfavorable clinical features, such as older age, antecedent myeloid disorders, and adverse risk factors (mutations in RUNX1 and ASXL1). Furthermore, they had significantly shorter event-free and overall survival. Notably, in European LeukemiaNet (ELN) 2017 favorableand intermediate-risk groups, SF3B1 mutations were indicative of relatively poor prognosis. In addition, patients carrying concomitant SF mutations and RUNX1 mutations had a particularly adverse prognosis. In patients without any of the 4 most common SF mutations, RUNX1 mutations were associated with relatively good outcome, which was comparable to that of intermediate-risk patients. In this study, we propose that SF mutations be considered for incorporation into prognostic classification systems. First, SF3B1 mutations could be considered an intermediate prognostic factor when co-occurring with favorable risk features and as an adverse prognostic factor for patients currently categorized as having intermediate risk, according to the ELN 2017 classification. Second, the prognostic value of the current adverse factor RUNX1 mutations seems to be limited to its co-occurrence with SF mutations.

Originele taal-2Engels
Pagina's (van-tot)3254-3265
Aantal pagina's12
TijdschriftBlood Advances
Nummer van het tijdschrift17
StatusGepubliceerd - 14 sep. 2021
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification'. Samen vormen ze een unieke vingerafdruk.

Citeer dit